We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
West Virginia’s Supreme Court declined to expand the state’s product liability law to cover claims against branded drugs for harm caused by their generics. Read More
Gauging the 340B drug discount program’s effectiveness requires more price transparency and clearer guidance, expert witnesses told the Senate health committee Tuesday. Read More
In the latest development in the Michael Cohen-Novartis scandal, the U.S. Senate Committee on Finance pressured Novartis CEO Vasant Narasimhan for contracts and communications made between the pharma company and the president’s attorney. Read More
A federal appeals court affirmed the dismissal of a lawsuit brought by the nonprofit AIDS Healthcare Foundation (AHF) challenging Gilead’s patents on several of its HIV drugs. Read More